

Drugs and Devices Division

Drug Submission Status

Report for December 2019

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Fingolimod	Gilenya	fingolimod	0.5mg	capsule	02487772
Accel Pharma Inc.	Accel-Rizatriptan ODT	Maxalt RPD	rizatriptan benzoate	5mg	ODT	02483270
Accel Pharma Inc.	Accel-Rizatriptan ODT	Maxalt RPD	rizatriptan benzoate	10mg	ODT	02483289
Apotex Inc.	Apo-Dasatinib	Sprycel	dasatinib	20mg	FC tablet	02470705
Apotex Inc.	Apo-Dasatinib	Sprycel	dasatinib	50mg	FC tablet	02470713

Apotex Inc.	Apo-Dasatinib	Sprycel	dasatinib	70mg	FC tablet	02481499
Apotex Inc.	Apo-Dasatinib	Sprycel	dasatinib	80mg	FC tablet	02481502
Apotex Inc.	Apo-Dasatinib	Sprycel	dasatinib	100mg	FC tablet	02470721
Odan Laboratories Ltd.	Odan Levocarnitine	Carnitor	levocarnitine	100mg/mL	oral solution	02492105